
Please try another search
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Roy Lester Freeman | 71 | - | Chairman of Scientific Advisory Board |
Andrew I. Koven | 66 | 2021 | Independent Chairman of the Board |
D. Gordon Strickland | 77 | 2022 | Independent Director |
Michael H. Salsbury | 74 | 2019 | Independent Director |
Jason L. Groves | 53 | 2019 | Independent Director |
Hyung-Heon Kim | 49 | 2021 | CEO, President & Director |
Heon Kim Hyung | 48 | 2021 | CEO, President & Director |
Mark A. Glickman | 59 | 2023 | Independent Director |
Angela Fitch | - | - | Member of Scientific Advisory Board |
Lee Kaplan | - | - | Member of Scientific Advisory Board |
Carel le Roux | - | - | Member of Scientific Advisory Board |
James Patrick Tursi | 60 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review